Parkinson’s UK and Domainex collaborate to develop therapies targeting neuroinflammation
3 February 2022 Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, and Domainex Ltd., today announce a...
Parkinson’s UK invests £185K in new company to develop therapies targeting lysosomal dysfunction
25 January 2022 Through its innovative Parkinson’s Virtual Biotech, Parkinson’s UK is investing £185,000 in EndLyz Therapeutics, Inc....
Parkinson’s UK invests up to £3 million in a promising project which could slow progression
7 December 2021 Parkinson’s UK, Europe’s largest charitable funder of research into the condition, is leading a project to develop...
First Patient Dosed in Phase 2a Trial of NLX-112 for the Treatment of L-DOPA Induced Dyskinesia
November 30, 2021 Neurolixis, a clinical-stage biopharmaceutical company focused on advancing novel therapies to treat central nervous...
Professor Howard Federoff joins Board of Vivifi Biotech
24 September 2021 Parkinson’s Virtual Biotech is pleased to announce the appointment of world-leading Parkinson’s expert, Professor...
Parkinson’s UK invests further £490K in NRG Therapeutics Parkinson’s Drug Discovery Programme
Cambridge, UK, 23 August 2021 - NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial...